REGENERON PHARMACEUTICALS, INC. (REGN) Financials
Annual revenue, profitability and per-share results for REGENERON PHARMACEUTICALS, INC., as reported in SEC filings.
Revenue · FY2025
$14.34B
▲ 1.0%YoY
Net income · FY2025
$4.50B
▲ 2.1%YoY
Diluted EPS · FY2025
$41.48
▲ 8.2%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $14.34B | $4.50B | — | $41.48 | $4.08B | 24.9% | +1.0% |
| FY2024 | $14.20B | $4.41B | — | $38.34 | $3.66B | 28.1% | +8.3% |
| FY2023 | $13.12B | $3.95B | — | $34.77 | $1.41B | 30.9% | +7.8% |
| FY2022 | $12.17B | $4.34B | — | $38.22 | $4.42B | 38.9% | -24.3% |
Figures as reported in REGENERON PHARMACEUTICALS, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a REGN filing.
Get an email when REGN files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.